EISAI SUBMITS APPLICATIONS FOR REEVALUATION OF EFFICACY AND PARTIAL CHANGE TO LABEL OF EGG WHITE LYSOZYME PREPARATION NEUZYM® BASED ON RESULTS OF REEVALUATION STUDIES

EISAI

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its pharmaceutical manufacturing and marketing subsidiary Sannova Co., Ltd. (Headquarters: Gunma Prefecture, President: Toru Takekawa, “Sannova”) has submitted an application for reevaluation of the indication of bronchitis, bronchial asthma and bronchiectasis for egg white lysozyme preparation Neuzym® (lysozyme hydrochloride, “lysozyme”). At the same time, Sannova has also submitted an application for a partial label change to remove chronic sinusitis as an approved indication for Neuzym. The Neuzym series consists of six products -Neuzym Tablets (10 mg, 30 mg, 90 mg), Neuzym Granules (10%), Neuzym Fine Granules (20%) and Neuzym Syrup (0.5%). While Sannova is the manufacturing and marketing authorization holder of Neuzym, Eisai is responsible for marketing the products.